18-Apr-2024 3QFY2024 Results and Investor Conference Call Video

18-Apr-2024 Investor Presentation - April 2024

11-Apr-2024 Nyrada CEO James Bonner and SAB Chair Gary Housley interview with Proactive Investors

11-Apr-2024 3QFY2024 Results and Investor Conference Call

10-Apr-2024 Quarterly Activities Report and Appendix 4C

3-Apr-2024 2024 EGM Letter to Shareholders and Proxy

2-Apr-2024 2024 EGM Letter to Shareholders and Proxy

2-Apr-2024 2024 EGM Notice of Meeting and Proxy

2-Apr-2024 2024 EGM Letter to Shareholders and Proxy

2-Apr-2024 2024 EGM Notice of Meeting and Proxy

2-Apr-2024 2024 EGM Letter to Shareholders and Proxy

2-Apr-2024 2024 EGM Notice of Meeting and Proxy

28-Mar-2024 Nyrada Commences Key Brain Injury Program Preclinical Study

15-Mar-2024 Corporate Governance

15-Mar-2024 Certificate of Incorporation

15-Mar-2024 The Company By-Laws

15-Mar-2024 Notice of Change of Interests of Substantial Securityholder

15-Mar-2024 Cleansing Statement

15-Mar-2024 Application for quotation of securities - NYR

15-Mar-2024 Amended and Restated Certificate of Incorporation and Bylaw

15-Mar-2024 ‘Tide is turning for the healthcare sector’ – ASX biotechs making strong gains in 2024 Part 2

14-Mar-2024 Change of Director's Interest Notice - CC

14-Mar-2024 Change of Director's Interest Notice - MF

14-Mar-2024 Change of Director's Interest Notice - RW

14-Mar-2024 Change of Director's Interest Notice - JM

14-Mar-2024 Notification of cessation of securities - NYR

11-Mar-2024 4 of the best performing pharma & biotech stocks to begin the new year

8-Mar-2024 Company Overview

8-Mar-2024 4 of the Best Performing Pharma & Biotech Stocks to Begin the New Year

8-Mar-2024 The next Neuren? Nyrada chases after two big markets

6-Mar-2024 Nyrada Successfully Raises $1.755 Million via Placement

6-Mar-2024 Proposed issue of securities - NYR

6-Mar-2024 Nyrada Successfully Raises $1.755 Million via Placement

4-Mar-2024 Trading Halt

1-Mar-2024 This week’s Bulls N’ Bears top ASX runner is … Nyrada.

29-Feb-2024 Guess which ASX pharmaceuticals stock is up 400% in 2 days

28-Feb-2024 Nyrada CEO exclusively shares 3 reasons for stunning +420pc session

28-Feb-2024 Nyrada CEO James Bonner interview with 180 Markets

28-Feb-2024 Nyrada CEO James Bonner interview with Financial News Network

28-Feb-2024 Significant Neuroprotection in NYR Preclinical Brain Injury

20-Feb-2024 Nyrada Half Year Results FY2024

20-Feb-2024 Appendix 4D and Half Year Report to 31 December 2023

19-Jan-2024 Amended and Restated Certificate of Incorporation and Bylaws

17-Jan-2024 Quarterly Activities Report and Appendix 4C

8-Dec-2023 Nyrada Receives A$3.54M R&D Tax Incentive Rebate

27-Nov-2023 Cardiovascular Program

27-Nov-2023 Lead Drug Development

23-Nov-2023 Past Shareholder Meetings

20-Nov-2023 Nyrada Annual General Meeting Results

20-Nov-2023 Nyrada AGM 2023 CEO Presentation

20-Nov-2023 Nyrada AGM 2023 Chair Address

1-Nov-2023 2023 AGM Chair Letter to Shareholders

24-Oct-2023 Proxy Form

17-Oct-2023 2023 AGM Notice of Meeting and Proxy

17-Oct-2023 2023 AGM Letter to Shareholders and Proxy

13-Oct-2023 Quarterly Activities Report and Appendix 4C

22-Sep-2023 Privacy Policy

28-Aug-2023 Nyrada Full Year Results FY2023

28-Aug-2023 Annual Report for year ended 30 June 2023

28-Aug-2023 Preliminary Final Report

28-Aug-2023 Appendix 4G and Corporate Governance Statement

28-Jul-2023 Quarterly Activities Report and Appendix 4C

20-Jul-2023 Nyrada Review of Operating Costs

18-Jul-2023 TRPC Channels Activated by G Protein‑Coupled Receptors Drive Ca2+ Dysregulation Leading to Secondary Brain Injury in the Mouse Model

26-Jun-2023 Cholesterol-Lowering Program Update

9-Jun-2023 Brain Injury Program Preclinical Development Update

26-May-2023 Cholesterol-Lowering Program Preclinical Studies Completed

26-Apr-2023 Quarterly Activities Report and Appendix 4C

11-Apr-2023 Cholesterol-Lowering Program Preclinical Development Update

17-Mar-2023 Drug Development Pathway

24-Feb-2023 Nyrada Half Year Results FY2023

24-Feb-2023 Appendix 4D and Half Year Report to 31 December 2022

20-Feb-2023 Technical Glossary

20-Feb-2023 Brain Injury Program

30-Jan-2023 Quarterly Activities Report and Appendix 4C

18-Jan-2023 Collaboration with Walter Reed and UNSW Extended to 2025

16-Jan-2023 Notification of cessation of securities - NYR

11-Jan-2023 Brain Injury Program Update

5-Dec-2022 James Bonnar (CEO) speaks to Tony Locantro (Alto Capital) about Nyrada’s Phase I Cholesterol Lowering Study

21-Nov-2022 Results of Meeting

21-Nov-2022 AGM Presentation by James Bonnar CEO

21-Nov-2022 Nyrada AGM 2022 Chairmans Address

18-Nov-2022 Nyrada Receives A$1.2M R&D Tax Incentive Rebate

27-Oct-2022 CEO Remuneration Update

26-Oct-2022 Quarterly Activities Report and Appendix 4C

21-Oct-2022 Proxy Form

18-Oct-2022 2022 AGM Letter to Shareholders and Proxy

18-Oct-2022 2022 AGM Notice of Meeting and Proxy

10-Oct-2022 A Novel, Orally Bioavailable, Small-Molecule Inhibitor of PCSK9 With Significant Cholesterol-Lowering Properties In Vivo

10-Oct-2022 Efficacy Study Published in Journal of Lipid Research

29-Sep-2022 Nyrada (ASX:NYR) CEO, James Bonnar presentation to ShareCafe’s Hidden Gems Webinar, September 2022

29-Sep-2022 Presentation to ShareCafe Hidden Gems Webinar

5-Sep-2022 Presentation to E&P Small Caps Health Care Conference

29-Aug-2022 Nyrada Reports Full Year FY2022 Results

29-Aug-2022 Annual Report to June 30 2022

29-Aug-2022 Preliminary Final Report

29-Aug-2022 Appendix 4G and Corporate Governance Statement

2-Aug-2022 Nyrada Board Changes

2-Aug-2022 Initial Director's Interest Notice - GM

2-Aug-2022 Final Director's Interest Notice - PM

26-Jul-2022 Quarterly Activities Report and Appendix 4C

20-Jul-2022 Nyrada PCSK9 Inhibitor Tested in Model of Atherosclerosis

29-Jun-2022 Cholesterol-Lowering Program Update

7-Jun-2022 Corporate Presentation

6-Jun-2022 Brain Injury Program Target Unveiled and Phase I Update

17-May-2022 European Patent to be Granted for Cholesterol-Lowering Drug

19-Apr-2022 Nyrada Quarterly Activities Report & Appendix 4C

30-Mar-2022 Investor Roadshow Presentation

29-Mar-2022 New Drug Offers Potential Oral Treatment for Concussion

2-Mar-2022 Presentation to Meet the CEO Life Sciences Edition

25-Feb-2022 Nyrada Half Year Results FY2022

25-Feb-2022 Appendix 4D and Half Year Report to 31 December 2021

28-Jan-2022 Investor Welcome

27-Jan-2022 Share Price Information

21-Jan-2022 Nyrada Quarterly Activities Report & Appendix 4C

17-Jan-2022 Application for quotation of securities - NYR

17-Jan-2022 Change of Director's Interest Notice - ID

17-Jan-2022 Change of Director's Interest Notice - MF

17-Jan-2022 Change of Director's Interest Notice - RW

17-Jan-2022 Change of Director's Interest Notice - JM

17-Jan-2022 Change of Director's Interest Notice - CC

17-Jan-2022 Change of Director's Interest Notice - PM

12-Jan-2022 Nyrada Receives A$1.3M R&D Tax Incentive Rebate

4-Jan-2022 Brain Injury Program Update and Pathway to Phase I

22-Dec-2021 Cholesterol-Lowering Program Pathway to Phase I

10-Dec-2021 Release of Securities from Escrow

19-Nov-2021 Nyrada Annual General Meeting Results

19-Nov-2021 Annual General Meeting Presentation

19-Nov-2021 Nyrada AGM 2021 Chairman's Address

26-Oct-2021 Nyrada Quarterly Activities Report & Appendix 4C

19-Oct-2021 2021 AGM Notice of Meeting and Proxy

19-Oct-2021 2021 AGM Letter to Shareholders and Proxy

16-Sep-2021 Nyrada (ASX:NYR) CEO, James Bonnar presents at the ASX Small and Mid-Cap Conference

16-Sep-2021 Nyrada (ASX:NYR) CEO, James Bonnar interview with Andrew Scott (Proactive Investors) at the ASX Small and Mid-Cap Conference, September 2021

14-Sep-2021 Nyrada (ASX:NYR) CEO, James Bonnar presents at the ASX Small and Mid-Cap Conference

14-Sep-2021 Nyrada (NYR: ASX) CEO, James Bonnar interview with Andrew Scott (Proactive Investors) at the ASX Small and Mid-Cap Conference, September 2021

13-Sep-2021 Presentation to ASX Small and Mid-Cap Conference

10-Sep-2021 RaaS Report - Nyrada

Report prepared as part of ASX Small and Mid-Cap Conference - 14 September 2021.

7-Sep-2021 Contact Us

6-Sep-2021 Anti-Bribery and Corruption Policy

6-Sep-2021 Nyrada Inc. Whistleblower Policy

6-Sep-2021 SECURITIES TRADING POLICY

6-Sep-2021 REMUNERATION & NOMINATION COMMITTEE CHARTER

6-Sep-2021 DIVERSITY POLICY

6-Sep-2021 COMMUNICATION AND DISCLOSURE POLICY

6-Sep-2021 CODE OF CONDUCT

6-Sep-2021 BOARD CHARTER

6-Sep-2021 AUDIT & RISK COMMITTEE CHARTER

6-Sep-2021 NYRADA INC (ASX:NYR) – BOARD SKILLS MATRIX SUMMARY

6-Sep-2021 Nyrada Statement of Values

3-Sep-2021 Updated Share Trading Policy

30-Aug-2021 Nyrada Reports Full Year FY2021 Results

30-Aug-2021 Annual Report to 30 June 2021

30-Aug-2021 Preliminary Final Report

30-Aug-2021 Appendix 4G and Corporate Governance Statement

13-Aug-2021 NYX-PCSK9i In Vivo Study Exploratory Analysis Results

30-Jul-2021 Nyrada Announces US Patent Grant for PCSK9 Inhibitor

27-Jul-2021 Nyrada Quarterly Activities Report & Appendix 4C

2-Jul-2021 Nyrada (ASX:NYR) CEO, James Bonnar interview with FNN, June 2021

1-Jul-2021 Nyrada (ASX:NYR) interview with Finance News Network, June 2021

30-Jun-2021 Change of Director's Interest Notice - CC

30-Jun-2021 Change of Director's Interest Notice - ID

30-Jun-2021 Change of Director's Interest Notice - RW

30-Jun-2021 Change of Director's Interest Notice - MF

30-Jun-2021 Change of Director's Interest Notice - PM

30-Jun-2021 Change of Director's Interest Notice - JM

30-Jun-2021 Change in substantial holding

29-Jun-2021 Cleansing Statement

29-Jun-2021 Confirmation of Capital Structure, CDIs on Issue

29-Jun-2021 Notification regarding unquoted securities - NYR

29-Jun-2021 Application for quotation of securities - NYR

29-Jun-2021 NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction

16-Jun-2021 Results of Meeting

15-Jun-2021 Improved Drug Candidate Selected for WRAIR Studies

4-Jun-2021 Discovery Program

11-May-2021 Notice of Extraordinary General Meeting/Proxy Form

6-May-2021 Nyrada Receives A$1.0M R&D Tax Incentive Rebate

5-May-2021 NYR Announces New Potent Cholesterol-Lowering Candidates

26-Apr-2021 Change of Registered Office and Principal Place of Business

20-Apr-2021 Nyrada Quarterly Activities Report & Appendix 4C

30-Mar-2021 Change in substantial holding

30-Mar-2021 Ceasing to be a substantial holder

30-Mar-2021 Change in substantial holding

30-Mar-2021 Cleansing Statement

30-Mar-2021 Appendix 2A

25-Mar-2021 Change in substantial holding

22-Mar-2021 Proposed issue of Securities - NYR

22-Mar-2021 Nyrada Receives Firm Commitments to Raise A$11 Million

18-Mar-2021 Nyrada Investor Presentation

17-Mar-2021 Trading Halt

5-Mar-2021 Change of Director's Interest Notice - JM

2-Mar-2021 Nyrada Newsletter February 2021

25-Feb-2021 Nyrada (ASX:NYR) CEO, James Bonnar provides update on lead drug development programs at Finance News Network CEO Showcase, February 2021

24-Feb-2021 Appendix 3G

24-Feb-2021 Change of Director's Interest Notice - MF

23-Feb-2021 Nyrada (ASX:NYR) CEO, James Bonnar provides update on lead drug development programs at Finance News Network CEO Showcase, February 2021

23-Feb-2021 Investor Presentation to Finance News Network CEO Showcase

22-Feb-2021 Nyrada Reports Half Year FY2021 Results

22-Feb-2021 Appendix 4D and Half Year Accounts

16-Feb-2021 Lapsing of balance of Unlisted SAB Options

16-Feb-2021 Cleansing Statement

16-Feb-2021 Appendix 2A

4-Feb-2021 Nyrada (ASX:NYR) discusses collaboration with the Walter Reed Army Institute of Research and UNSW Sydney, February 2021

3-Feb-2021 Nyrada (ASX:NYR) discusses collaboration with the Walter Reed Army Institute of Research and UNSW Sydney, February 2021

1-Feb-2021 NYR Secures Collaboration with Walter Reed and UNSW

29-Jan-2021 Trading Halt

28-Jan-2021 Nyrada Quarterly Activities Report & Appendix 4C

25-Jan-2021 Nyrada Reports Further Results from Cholesterol Study

22-Jan-2021 Unlisted Scientific Advisory Board Options Expiry 15 Feb 21

18-Jan-2021 Change of Director's Interest Notice - ID

18-Jan-2021 Appendix 3G

12-Jan-2021 Biotech Dispatch: Nyrada reports 'encouraging' early efficacy results from PCSK9i program

Australian biotech news website, BiotechDispatch said Nyrada had reported "encouraging efficacy results" from an in vivo study involving its NYX-PCSK9i drug candidate.

Read more here

8-Jan-2021 Nyrada (ASX:NYR) discusses progress in cholesterol-lowering drug program, January 2021

7-Jan-2021 Release of Securities from Escrow

6-Jan-2021 Nyrada (ASX:NYR) discusses progress in cholesterol-lowering drug program, January 2021

6-Jan-2021 Change in substantial holding

21-Dec-2020 57% Cholesterol Reduction from NYX-PCSK9i In Vivo Study

14-Dec-2020 Appointment of New Auditor

8-Dec-2020 Change in substantial holding

2-Dec-2020 Cleansing Statement

2-Dec-2020 Appendix 2A

1-Dec-2020 Working at Nyrada Inc

26-Nov-2020 Change of Director's Interest Notice - JM

25-Nov-2020 Change of Director's Interest Notice - MF

25-Nov-2020 Appendix 2A

19-Nov-2020 Nyrada Annual General Meeting Results

19-Nov-2020 Presentation to 2020 Annual General Meeting of Shareholders

19-Nov-2020 Nyrada AGM 2020 Chairmans Address

18-Nov-2020 Pitt Street Research Interview with Nyrada CEO, Mr James Bonnar

17-Nov-2020 Nyrada Inc - Hidden Gems Webinar Presentation

17-Nov-2020 Pitt Street Research Interview with Nyrada CEO, Mr James Bonnar

16-Nov-2020 Release of Securities from Escrow

9-Nov-2020 Unlisted Convertible Note Options Expiring 30 November 2020

5-Nov-2020 Pitt Street Research Initiation Report

3-Nov-2020 2020 Annual General Meeting Reminder

19-Oct-2020 Letter to Shareholders and Proxy Form in relation to AGM

19-Oct-2020 Notice of Annual General Meeting and Proxy Form

13-Oct-2020 Nyrada Quarterly Activities Report & Appendix 4C

13-Oct-2020 Appendix 4C - September 2020 Quarterly Report

24-Sep-2020 Nyrada Newsletter September 2020

17-Sep-2020 Notification of Date of 2020 Annual General Meeting

11-Sep-2020 Change of Director's Interest Notice - JM

11-Sep-2020 Nyrada Inc - Hidden Gems Webinar Presentation

11-Sep-2020 Corporate Presentation for ShareCafe Hidden Gems Webinar

9-Sep-2020 Nyrada Investor Webinar

8-Sep-2020 Nyrada 2020 Appendix 4G and Corporate Governance Statement

8-Sep-2020 Initial Director's Interest Notice - ID

8-Sep-2020 Final Director's Interest Notice - GK

8-Sep-2020 Annual Report to 30 June 2020

8-Sep-2020 Appendix 4G and Corporate Governance Statement

31-Aug-2020 FY 2020 Appendix 4E Preliminary Financial Report

31-Aug-2020 FY 2020 Appendix 4E and Preliminary Financial Report

31-Aug-2020 FY 2020 Appendix 4E Preliminary Financial Report

31-Aug-2020 Nyrada Board Changes

13-Aug-2020 Nyrada July/August 2020 webinar recording: New Therapies for Cardiovascular and Neurological Diseases, August 2020

11-Aug-2020 Nyrada July/August 2020 webinar recording: New Therapies for Cardiovascular and Neurological Diseases, August 2020

30-Jul-2020 Nyrada Global Webcast Invitation

29-Jul-2020 Nyrada A$1.0M R&D Tax Rebate & Use of Funds Annexure

23-Jul-2020 Nyrada Roadshow Corporate Presentation

23-Jul-2020 Nyrada Roadshow Corporate Presentation July/August 2020

23-Jul-2020 Nyrada Roadshow Corporate Presentation

22-Jul-2020 Appendix 4C - June 2020 Quarterly Report

22-Jul-2020 Appendix 4C - June 2020 quarterly report

15-Jul-2020 Nyrada Brain Injury Drug Pharmacokinetic Study Results

9-Jul-2020 Nyrada Brain Injury Data Published by Premier US Military Health Conference

9-Jul-2020 Nyrada Abstract_MHSRS 2020 conference

9-Jul-2020 Nyrada Brain Injury Data Published by Premier US Military Health Conference

8-Jul-2020 Change in substantial holding

6-Jul-2020 Nyrada Cholesterol-Lowering Drug Study Results

2-Jul-2020 Nyrada presents at the Reach Markets "Meet the CEO's" virtual event June 24, 2020

25-Jun-2020 Nyrada Newsletter June 2020

24-Jun-2020 Nyrada presents at the Reach Markets "Meet the CEO's" virtual event June 24, 2020

24-Jun-2020 Corporate Presentation for the Reach Markets Virtual Event

25-May-2020 Milestone Achieved in the Nyrada Brain Injury Program

5-May-2020 Nyrada Virtual Investor Event 30 April 2020

30-Apr-2020 Nyrada Virtual Investor Event 30 April 2020

30-Apr-2020 Nyrada Preclinical Program & Corporate Update Presentation

27-Apr-2020 Change of Director's Interest Notice - JM

22-Apr-2020 Appointment of New Chief Financial Officer

20-Apr-2020 Preclinical Program & Corporate Update Global Webinar

14-Apr-2020 Appendix 4C - March 2020 Quarterly Report

14-Apr-2020 Appendix 4C - March 2020 quarterly

6-Apr-2020 Nyrada Newsletter Released

16-Mar-2020 Update on Progress in Nyrada Programs

27-Feb-2020 Nyrada Inc. Corporate Presentation February 2020

25-Feb-2020 Investor Welcome

25-Feb-2020 Appendix 4D and Half Yearly Accounts

25-Feb-2020 Appendix 4D and Half Year Accounts

14-Feb-2020 Nyrada (ASX: NYR) CEO James Bonnar discusses the company’s commercialisation plans

11-Feb-2020 Hypercholesterolaemia Drug Candidate Animation

11-Feb-2020 Significant advance in Nyrada PCSK9i program published

11-Feb-2020 A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove

4-Feb-2020 Nyrada Brain Injury Explainer Animation

23-Jan-2020 Nyrada (ASX:NYR) - new therapies for cardiovascular and neurological disorders

23-Jan-2020 NYRADA Corporate Governance Statement 2019

20-Jan-2020 Nyrada Inc - Chairman's letter to shareholders

20-Jan-2020 Becoming a substantial holder

17-Jan-2020 Nyrada Inc - Corporate Presentation

16-Jan-2020 NOX: Listing of Nyrada Inc. spin-off on ASX

16-Jan-2020 NYR Commences Trading on the ASX

16-Jan-2020 Becoming a substantial holder

16-Jan-2020 Initial Director's Interest Notice

15-Jan-2020 Success

15-Jan-2020 Autoimmune

15-Jan-2020 Regulation S-Foreign Ownership Restrictions

14-Jan-2020 Confirmation and Waiver under ASX Listing Rules

14-Jan-2020 Pre-Quotation Disclosure

14-Jan-2020 Updated Pro-forma - Financial Position and Commitments

14-Jan-2020 Securities Trading Policy

14-Jan-2020 Capital Structure and Restricted Securities

14-Jan-2020 Financial Statements Year End 30 June 2019

14-Jan-2020 Financial Statements Year End 30 June 2018

14-Jan-2020 Corporate Governance Statement

14-Jan-2020 Equity Incentive Plan

14-Jan-2020 Amended and Restated Certificate of Incorporation and Bylaws

14-Jan-2020 Supplementary Prospectus

14-Jan-2020 Prospectus

14-Jan-2020 Appendix 1A, Information Form and Checklist, Annexure 3

14-Jan-2020 Distribution Schedule

14-Jan-2020 Top 20 Securityholders

14-Jan-2020 ASX Market Release - Admission and Quotation

14-Jan-2020 Inflammation/Pain

31-Dec-2019 Overseas Investors

30-Dec-2019 Whistleblower Policy

6-Dec-2019 Code of Conduct

6-Dec-2019 Securities Trading Policy

6-Dec-2019 Diversity Policy

6-Dec-2019 Risk Management Policy

6-Dec-2019 Communication and Disclosure Policy

6-Dec-2019 Audit and Risk Committee Charter

6-Dec-2019 Remuneration and Nomination Committee Charter

6-Dec-2019 Board Charter

14-Aug-2019 Nyrada (ASX:NYR) targeting cholesterol-lowering drug candidate

14-Aug-2019 FNN Interview : Introduction to Nyrada, Inc.

2-Aug-2019 NOX Releases Initial Newsletter for Nyrada Subsidiary

2-Aug-2019 Defense TechConnect Summit and Expo. October 8-10 2019, Maryland. USA

16-Jul-2019 Board Changes Ahead of Corporate Growth

16-Jul-2019 Thank You

13-Jul-2011 Share Price Information

ASXData


Latest Stock Price
ASX (20 min delay) 29/04/2024 7:36 AM
Code:	NYR
Last:	###
Open:	###
High:	###
Low:	###
Vol:	###


	180 day share price chart (A$)

	Click for full stock chart

	Email Alerts:
	Keep informed of all company notices by joining our free Email Alerts service. Click here to join Email Alerts

###

ASX (20 min delay) 29/04/2024 7:36 AM